Cerecor Inc. CERC Cash Flow

Cerecor inc. (CERC)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15
Operating activities
Net loss
-29,735	-16,072	-23,252	-43,839	-43,624	-40,052	-37,585	5,738	9,947	11,869	13,322	-11,566	-13,292	-16,471	-18,481	-13,003	-12,392	-10,490	0	0	0
Adjustments to reconcile net loss used in operating activities:
Depreciation and amortization
3,238	3,883	4,487	4,495	4,630	4,554	3,741	2,676	1,442	425	0	0	0	-	-	-	-	-	-	-	-
Depreciation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	24	-	0	0	0
Stock-based compensation
3,051	2,532	2,576	2,703	2,784	2,431	2,101	1,420	1,067	1,157	1,107	1,131	1,089	1,694	1,512	1,253	1,281	394	0	0	0
Acquired in-process research and development, including transaction costs
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred taxes
31	16	60	-21	-26	-16	-880	-808	-816	-832	0	0	0	-	-	-	-	-	-	-	-
Amortization of inventory fair value associated with acquisition of TRx and Avadel's pediatric products
84	107	145	163	277	300	400	315	183	137	0	0	0	-	-	-	-	-	-	-	-
Change in fair value of Investment in Aytu
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liability and unit purchase option liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Change in fair value of warrant liability and unit purchase option liability
-54	3	-54	-15	-0	-25	50	47	49	29	0	0	0	-	-	-	-	-1,313	0	0	0
Change in value of Guarantee
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	302	327	350	112	20	48	86	123	162	223	299	276	293	0	0	0
Change in fair value of contingent consideration
-1,189	-1,009	-1,311	-1,029	-24	58	360	276	262	0	0	0	0	-	-	-	-	-	-	-	-
Other
0	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Changes in assets and liabilities:
Accounts receivable, net
-523	-1,658	1,947	-448	-111	222	320	620	142	247	0	0	0	-	-	-	-	-	-	-	-
Grants receivable
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Other receivables
-3,219	-5,120	-6,056	-2,709	2,710	2,277	3,499	88	55	427	0	0	0	-	-	-	-	-	-	-	-
Inventory, net
-496	-532	-516	-759	-284	311	251	641	578	24	0	0	0	-	-	-	-	-	-	-	-
Grants receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Prepaid expenses and other assets
1,175	917	409	-104	-110	241	200	-152	390	177	119	79	6	-22	-405	-305	-142	41	0	0	0
Escrowed cash receivable
-	-	-	-	-	-3,752	-3,750	3,757	3,754	3,752	0	0	0	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	15	0	0	0	-	-	-	0
Accounts payable
1,466	1,019	-709	-1,559	-1,981	82	966	2,419	2,377	96	-475	-412	-10	332	-477	-204	-131	-268	0	0	0
Income taxes payable
-1,814	-1,480	-1,180	-778	-451	-226	-1,034	2,171	2,266	2,259	0	0	0	-	-	-	-	-	-	-	-
Accrued expenses and other liabilities
-9,051	-6,835	-4,967	-919	9,705	7,792	7,889	4,664	2,508	2,044	-2,256	-859	-714	-119	3,420	1,274	1,767	1,121	0	0	0
Lease liability, net
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-21,718	-19,100	-19,475	-12,314	-5,969	-3,128	-3,701	15,960	14,534	12,578	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by (used in) operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-10,800	-	0	0	0
Investing activities
Net cash paid in merger with Aevi
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avadel pediatric products acquisition
-	-	-	-	-	0	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Purchase of property and equipment
96	262	761	795	711	564	80	47	40	23	17	17	27	34	0	0	0	-	-	-	-
Net cash used in investing activities
-1,527	-443	-761	634	718	865	-17,539	-18,936	-18,929	-18,912	0	0	0	-	-	-	-	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Financing activities
Proceeds from exercise of stock options and warrants
816	836	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from registered direct offering, net
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from shares purchased through employee stock purchase plan
-	-	-	-	-	72	19	19	410	46	0	0	0	-	-	-	-	-	-	-	-
Proceeds from sale of shares pursuant to common stock private placement, net
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from underwritten public offering, net
0	8,975	0	0	0	-	0	0	506	1,693	2,696	3,696	3,189	2,003	0	0	0	-	-	-	-
Payment of contingent consideration
653	881	725	673	523	294	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payment of long-term debt
231	256	73	48	24	0	0	606	1,499	2,374	3,228	3,458	3,385	3,314	0	0	0	-	-	-	-
Payment of offering costs
-	-	-	-	-	-	-	-	-	279	392	180	264	114	1,495	1,936	2,294	2,269	0	0	0
Net cash provided by financing activities
12,840	12,559	18,590	18,919	18,857	10,403	4,248	-196	3,979	3,737	0	0	0	-	-	-	-	-	-	-	-
Increase in cash, cash equivalents and restricted cash
-10,439	-7,017	-1,600	7,200	13,607	8,141	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
(Decrease) increase in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Supplemental disclosures of cash flow information
Cash paid for interest
787	1,050	1,050	1,050	743	525	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for taxes
1,741	1,803	1,680	1,206	732	354	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosures of non-cash activities
Issuance of common stock in Aevi Merger
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosures of non-cash investing and financing activities
Leased asset obtained in exchange for new operating lease liability
0	743	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	210	281	348	421	478	531	568	0	0	0
Net cash provided by (used in) financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	18,773	-	0	0	0
Increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-16,034	5,507	5,736	7,944	9,419	0	0	0